SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Lixte Biotechnology Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound